Oncolytics Biotech Inc

Oncolytics Biotech insiders add to their positions, showing confidence in its reovirus therapy while navigating cash‑tight biotech waters.

Oncolytics insider trading insights: Lee Chan Henry’s 10b5‑1 buy‑sell pattern, market‑timed gains, and disciplined capital strategy explained.

Oncolytics insider buys signal confidence in REOLYSIN’s future: SVP Lee Chan Henry’s April 2026 ADS purchases highlight a long‑term bullish stance and a potential buying opportunity.

Oncolytics insider buying: SVP Lee Chan Henry’s recent ADS purchase signals executive confidence in the reovirus pipeline, hinting at a potential upside if clinical milestones are met.

Oncolytics insider buys signal renewed optimism for its reovirus platform; see how Henry’s accumulation could spark investor interest.

Oncolytics Biotech’s CEO and top execs are buying shares amid volatile price action, signaling confidence in REOLYSIN’s future and offering investors a potential hedge against short‑term swings.

Oncolytics CEO’s fresh share buys signal confidence in its reovirus cancer therapy; watch upcoming trial data and FDA milestones for potential price lift.

Oncolytics insider buy: SVP‑General Counsel Lee Chan Henry’s 2026 purchase after FDA Fast‑Track boosts confidence, shows disciplined strategy and potential upside.

Oncolytics insider buying signals confidence: SVP Lee Chan Henry’s recent $331.76 ADS purchase, above market price, highlights optimism on the pelareorep pipeline and strategic shifts.